论文部分内容阅读
美国Amgen公司已开始对巨核细胞生长发育因子（MGDF）进行I期临床试验,距其首次公布发现血小板刺激蛋白仅10个月。这使Amgen公司成为此细胞因子商品开发的领先者。 血小板生长因子临床开发的领先可转化为巨大的收益,每年有数十万血小板减少症病人需要治疗。这个问题主要是癌症病人的放疗和/或化疗的副作用。美国每年需进行1000万次血小板输注,一些分析家预测每年全球血小板刺激剂市场将超过10亿美元。
Amgen Corporation of the United States has begun a Phase I clinical trial of megakaryocyte growth and development factor (MGDF), only 10 months after its first announcement of a platelet stimulating protein. This makes Amgen a leader in the development of this cytokine product. The lead in clinical development of platelet growth factor can translate into tremendous benefits, with hundreds of thousands of thrombocytopenia patients requiring treatment each year. The problem is mainly the side effects of radiotherapy and / or chemotherapy in cancer patients. The United States needs 10 million platelet transfusions per year, with some analysts forecast that the global market for platelet stimulators will exceed $ 1 billion per year.